AI-Powered Digital Biomarker
AI analysis based on neuromuscular biosignals enables diagnostic support and quantitative assessment of disease severity for neuromuscular and musculoskeletal disorders.
The AI-Powered Digital Biomarker technology is
a proprietary artificial intelligence solution that quantitatively evaluates muscle-related biomarkers
based on biosignals measured from the neuromuscular system.
By doing so, it enables rapid and convenient support for diagnostic decision-making and severity assessment
across a wide range of neuromuscular and musculoskeletal disorders.
AI Digital Biomarkers
: Faster, Broader, More Consistent.
Improved operational efficiency
By reducing labor-intensive measurement procedures to an approximately 3-minute evaluation process, we enhance clinical and operational efficiency.
Expanded patient accessibility
We enable simple, non-invasive assessment for patients with limited mobility and for populations where conventional protocols are difficult to apply.
Enhanced reproducibility and standardization
By minimizing examiner-dependent variability and patient condition-related fluctuations, we support consistent interpretation through standardized quantitative metrics.
PNS Digital Biomarker
Digital Biomarkers for Diagnostic Support in Peripheral Nervous System Disorders
Sarcopenia Diagnostic Support
Myasthenia gravis (MG) Diagnostic Support
Sarcopenia and Myasthenia gravis (MG) have traditionally depended on expensive equipment, blood tests, invasive needle-based examinations, or patient-dependent performance, which has imposed significant burdens and limited accessibility.
EXOSYSTEMS applies a non-invasive approach that collects biosignals from the neuromuscular system and neuromuscular junction using skin-attached sensors and analyzes them with artificial intelligence.
This enables rapid and convenient measurement without requiring subjective patient effort and supports diagnostic decisions of clinicians without complex interpretation processes. As a result, the technology can be used for early screening and diagnostic support for sarcopenia and myasthenia gravis.
CNS Digital Biomarker
Digital Biomarkers for Severity Assessment and Diagnostic Support in Central Nervous System Disorders
Stroke / Hemiplegia Severity Assessment
Parkinson’s Disease Diagnostic Support
Motor Neuron Disease Severity Assessment
Stroke / Hemiplegia, Parkinson’s disease, and motor neuron diseases have traditionally relied on expensive imaging equipments, performance-based assessments, and subjective clinical judgment, leading to variability in results depending on patient condition and testing environments.
EXOSYSTEMS analyzes neuromuscular biosignals that can be obtained without requiring active patient movement by using artificial intelligence to quantitatively evaluate functional impairment in stroke and hemiplegia, disease-specific patterns in Parkinson’s disease, and the severity of motor neuron diseases.
By minimizing subjective interpretation and enabling short, standardized measurement, the technology of EXOSYSTEMS provides objective digital indicators that can be used for diagnostic support as well as for monitoring disease progression and rehabilitation outcome.
